Ability of linear length of positive margin in radical prostatectomy specimens to predict biochemical recurrence

Urology

Volumn 77, Issue 6, 2011, Pages 1409-1414

  Cao, Dengfeng ^a   Humphrey, Peter A ^a   Gao, Feng ^a   Tao, Yu ^a   Kibel, Adam S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LINEAR LENGTH OF A POSITIVE MARGIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; RECURRENT DISEASE; RISK ASSESSMENT; SURGICAL TECHNIQUE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; REGRESSION ANALYSIS; RISK; TREATMENT OUTCOME;

EID: 79957907516     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.10.059     Document Type: Article

References (26)

1. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003;62:866-871.
2. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3582-93. (Pubitemid 23152669)
3. Obek C, Sadek S, Lai S, et al. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology. 1999;54:682-688. (Pubitemid 29449430)
4. Stephenson AJ, Wood DP, Kattan MW, et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol. 2009;182:1357-1363.
5. Sofer M, Hamilton-Nelson KL, Civantos F, et al. Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol. 2002;167:2453-2456. (Pubitemid 34533144)
6. Kordan Y, Salem S, Chang SS, et al. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009;182:2695-2701.
7. Blute ML, Bostwick DG, Bergstralh EJ, et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997;50:733-739. (Pubitemid 27494995)
8. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20:286-292. (Pubitemid 26071509)
9. Resnick MJ, Canter DJ, Guzzo TJ, et al. Defining pathological variables to predict biochemical failure in patients with positive surgical margins at radical prostatectomy: implications for adjuvant radiotherapy. BJU Int. 2010;105:1377-1380.
10. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins' experience. Urol Clin North Am. 2001;28:555-565.
11. Chuang AY, Nielsen ME, Hernandez DJ, et al. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol. 2007;178:1306-1310. (Pubitemid 47368418)
12. Ochiai A, Sotelo T, Troncoso P, et al. Natural history of biochemical progression after radical prostatectomy based on length of a positive margin. Urology. 2008;71:308-312. (Pubitemid 351282340)
13. Babaian RJ, Troncoso P, Bhadkamkar VA, et al. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer. 2001;91:1414-1422. (Pubitemid 32319250)
14. Shikanov S, Song J, Royce C, et al. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009;182:139-144.
15. Vis AN, Schröder FH, van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol. 2006;50:258-265. (Pubitemid 44038060)
16. Emerson RE, Koch MO, Jones TD, et al. The influence of extent of surgical margin positivity on prostate specific antigen recurrence. J Clin Pathol. 2005;58:1028-1032. (Pubitemid 41416050)
17. Marks RA, Koch MO, Lopez-Beltran A, et al. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol. 2007;38:1207-1211. (Pubitemid 47058159)
18. Weldon VE, Tavel FR, Neuwirth H, et al. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol. 1995;153:1565-1569.
19. Srigley JR, Humphrey PA, Amin MB, et al, for the Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the prostate. Arch Pathol Lab Med. 2009;133:1568-1576.
20. Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy specimens: a comparative analysis of sampling methods. Am J Surg Pathol. 1992;16:315-324.
21. Edge SB, Bryd DR, Compton CC, et al, editors. AJCC Cancer Staging Manual. New York: Springer; 2009:457-468.
22. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387. (Pubitemid 26072233)
23. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-578. (Pubitemid 41140332)
24. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924-2930.
25. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956-962.
26. Lennernäs B, Edgren M, Häggman M, et al. Postoperative radiotherapy after prostatectomy-a review. Scand J Urol Nephrol. 2003;37:10-15.